Index | Experimental group (М ± m) | Control group (М ± m) |
n (number of patients) | 25 | 20 |
Age (years) | 23.9 ± 1.9 | 25.4 ± 2.2 |
BMI (kg/m2) | 30.7 ± 0.6 | 30.7 ± 0.6 |
Fasting plasma glucose (mmol/l) | 4.8 ± 0.09 | 4.6 ± 0.08 |
Basal insulin (pmol/l) | 137.3 ± 5.6 | 147.3 ± 7.2 |
Stimulated insulin (pmol/l) | 591.4 ± 9.1 | 579.2 ± 8.7 |
HOMA-IR | 5.7 ± 1.0 | 5.9 ± 1.0 |
Testosterone (ng/ml) (n = 8) | 0.89 ± 0.05 | 0.97 ± 0.07 |
Estradiol (pmol/l) | 239 ± 25.9 | 216 ± 23.4 |
Progesterone (nmol/) | 4.06 ± 0.08 | 4.86 ± 0.08 |
LH/FSH | 2.50 ± 0.13 | 2.60 ± 0.16 |
17-OHP (ng/ml) | 2.87 ± 0.15 | 2.13 ± 0.11 |
Average ovarial volume, ml | 12.4 ± 1.9 | 11.1 ± 1.6 |
Hyperinsulinemia, n (%) | 25 (100%) | 20 (100%) |
BMI > 25 kg/m2, n (%) | 8 (33%) | 7 (33%) |
Androgenic dermopathy, n (%) | 7 (28%) | 5 (25%) |
Hyperlipidemia, n (%) | 6 (24%) | 6 (30%) |
Acanthosis nigricans, n (%) | 4 (16%) | 2 (10%) |
IGT, n (%) | 3 (12%) | 1 (5%) |
IFG, n (%) | 2 (8%) | 2 (10%) |
Heterozygous carrier for 21-hydroxylase defect | 4 (8.9%) | - |